Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
VYNT similar filings
- 26 Oct 21 Other Events
- 16 Aug 21 Vyant Bio Reports Second Quarter 2021 Results and Provides Strategic Business Updates
- 17 May 21 Vyant Bio Reports First Quarter 2021 Results and Provides Strategic Business Update
- 5 Apr 21 Report of Independent Registered Public Accounting Firm
- 25 Mar 21 Cancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniX
- 16 Mar 21 Other Events
- 26 Feb 21 Entry into a Material Definitive Agreement
Filing view
External links
Exhibit 16.1
April 5, 2021
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Commissioners:
We have read the statements made by Vyant Bio, Inc. (formerly Cancer Genetics, Inc.) under Item 4.01 of its Form 8-K dated April 5, 2021. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Vyant Bio, Inc. (formerly Cancer Genetics, Inc.) contained therein.
Very truly yours,
/s/ Marcum LLP
Marcum LLP